Comparing the current results to its competitors, Zevra Therapeutics Inc reported Revenue increase in the 1 quarter 2026 by 42.17 % year on year. The sales growth was above Zevra Therapeutics Inc 's competitors' average revenue growth of 8.59 %, achieved in the same quarter.
Zevra Therapeutics Inc 's Comment on Competition and Industry Peers
The company operates in a highly competitive and rapidly evolving industry, facing competition from pharmaceutical and biotechnology firms, specialty pharmaceutical companies, generic drug manufacturers, drug delivery companies, as well as academic and research institutions. Competitors may develop drugs that offer greater efficacy, convenience, broader usage, lower cost, or improved safety profiles, and may possess superior manufacturing and marketing capabilities. Following the approval of MIPLYFFA, the FDA approved AQNEURSA, marketed by IntraBio, Inc., for a similar indication. OLPRUVA competes with both branded and generic phenylbutyrate products, including RAVICTI, marketed by Amgen Inc. (formerly Horizon Therapeutics), and PHEBURANE, marketed by Medunik USA. Authorized generics of RAVICTI, marketed by Par and Lupin, entered the market in late 2025. While there are drug candidates in clinical development for urea cycle disorders (UCDs), no active clinical trials for celiprolol are currently known.
Strong sales growth of 42.17 % in Overall company contributed to Zevra Therapeutics Inc increase in total revenue by 42.17 % Zevra Therapeutics Inc improved its market share in this segment, to approximately 0.24 %.
February 28, 2025
In the ever-evolving landscape of biotechnology and pharmaceuticals, the proactive approach to disease awareness and early diagnosis has never been more critical. Zevra Therapeutics Inc. a company dedicated to pioneering treatments for rare diseases, is stepping up its commitment with the launch of the Learn NPC, Read Between the Signs campaign. This new initiative aims to enhance understanding and recognition of Niemann-Pick Disease Type C (NPC), a rare genetic disorder that poses significant challenges in early diagnosis and treatment. Understanding Niemann-Pick Disease Type CNiemann-Pick Disease Type C is a lysosomal storage disorder that affects the body s ability to metabolize cholesterol and other lipi...
March 26, 2024
In development-stage biopharmaceutical industry, every new drug discovery and validation stands as a potential breakthrough for patients struggling with various health concerns - often unmet medical conditions. One such breakthrough announcement comes from Zevra Therapeutics regarding their Phase 2 Clinical Trials for KP1077, a novel treatment candidate for Idiopathic Hypersomnia (IH).Idiopathic Hypersomnia, a clinically recognized sleep disorder characterized by excessive daytime sleepiness despite normal or long sleep times, lacks effective and specific treatment options. The advent of KP1077 offers a ray of hope to IH patients - an assessment based on the recent top-line data revealed by Zevra Therapeutic...
December 27, 2023
Resubmission of the New Drug Application (NDA) for arimoclomol, an experimental therapeutic agent aimed at combating Niemann-Pick disease type C (NPC), has been announced by Zevra Therapeutics, Inc., a leading pharmaceutical organization specializing in the development of treatments for rare diseases. The resubmission, placed with the U.S. Food and Drug Administration (FDA), was issued on December 22, 2023.Niemann-Pick disease type C is a rare, genetically inherited disease primarily affecting children and adolescents. The illness invades neurological function, inhibiting the body s ability to process cholesterol and other lipids within cells. This enzymatic imbalance leads to the buildup of excessive amount...
Aditxt Inc operates on a business model that focuses on developing and commercializing technologies used in the field of biotechnology and personalized medicine. They leverage their expertise in genomics and diagnostics to offer innovative solutions that enable individuals to better understand and manage their health. Through their products and services, Aditxt aims to deliver personalized diagnostics and immune monitoring platforms to empower people in making informed decisions about their well-being.
Gain Therapeutics inc's business model revolves around using cutting-edge technology and innovative approaches to identify and develop small molecules that can effectively target and treat rare genetic diseases, such as lysosomal storage disorders and CNS-related disorders. They aim to leverage their expertise in computational drug design and protein structure analysis to discover potential drug candidates, which can then be developed and commercialized for therapeutic purposes.
Gossamer Bio Inc operates with a business model focused on the development and commercialization of novel therapies for patients with complex diseases. They leverage extensive scientific expertise and strategic partnerships to identify and advance a diverse pipeline of innovative medicines. Their goal is to deliver transformative therapies that address significant unmet medical needs and improve patient outcomes.
Harmony Biosciences Holdings Inc's business model revolves around the development and commercialization of innovative therapies for patients with sleep disorders.
Sources:
Zevra Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Zevra Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
